Overview of Pro-Fast

Property	Description
Active ingredient	Phentermine Hydrochloride
Form	Tablets or Capsules (Oral)
Pharmacological class	Anorectic / Sympathomimetic Amine
Common use	Short-term Weight Management (Exogenous Obesity)
Origin	Synthetic Compound

Defining Pro-Fast: Class, Composition, and Origin

Pro-Fast is a distinctive brand name for a single-ingredient, prescription-only medication whose active component is Phentermine Hydrochloride. The compound is chemically classified as a sympathomimetic amine, a type of drug recognized for stimulating the nervous system. The product is specifically categorized as an anorectic agent, reflecting its primary therapeutic function of suppressing appetite. This medicine is a synthetic compound, manufactured for oral use, and it stands as a single-ingredient product, differing from formulations that combine Phentermine with other drugs.

Pro-Fast's Core Purpose and Physical Form

The core purpose of Pro-Fast is to serve as a short-term pharmacological aid in the management of exogenous obesity for adult patients. Its use is clinically recognized, alongside diet and increased physical activity, to support weight reduction in adults. The product is manufactured and supplied in solid oral dosage forms, offered as either tablets or capsules, confirming the medication is administered via the oral route. This form factor ensures consistent delivery of the active agent for its intended purpose.

The High-Level Principle of Appetite Suppression

The fundamental mechanism that defines Pro-Fast is its ability to act as a powerful appetite suppressant. This action influences the body's internal signals for satiety and hunger, thereby lessening the intense desire to consume food and controlling cravings. This high-level principle is essential to the drug's utility, as the reduction in hunger sensation reliably facilitates the creation of the necessary caloric deficit, assisting patients in overcoming the challenges of adhering to a restricted-calorie diet.

What side effects are possible with Pro-Fast?

Possible side effects and safety information

The regulatory safety profile of Pro-Fast (Phentermine Hydrochloride) is defined by its action as a sympathomimetic amine, with documented adverse reactions primarily affecting the cardiovascular and central nervous systems. Official labeling classifies these effects by organ system.

System-Organ Class Effects

System	Documented Adverse Reactions (High-Level)
Cardiovascular	Palpitation, Tachycardia, and Elevation of Blood Pressure are listed.
Central Nervous System	Overstimulation, Restlessness, Insomnia, Dizziness, Tremor, and Headache are documented reactions.
Gastrointestinal	Dryness of the mouth, Unpleasant taste, Constipation, Diarrhea, and other gastrointestinal disturbances are noted.

Serious Adverse Reactions and Regulatory Warnings

Regulatory documents highlight the potential for serious, though rare, adverse reactions, including Primary Pulmonary Hypertension (PPH) and regurgitant cardiac valvular disease. More common serious events include Ischemic Events such as myocardial infarction and cardiac failure. The product is officially classified as a Schedule IV controlled substance, reflecting the government-recognized risk of abuse and dependence.

Contextual Safety Patterns

Safety is often tied to duration of use. If tolerance to the appetite-suppressing effect develops, regulatory guidance suggests discontinuation. Furthermore, abrupt cessation following prolonged high dosage administration is officially documented to result in symptoms such as extreme fatigue and mental depression. Chronic intoxication may be associated with severe dermatoses and psychosis.

Population-Specific Safety Notes

The label specifies that caution is required for use in older adults due to the greater likelihood of decreased organ function. Use is explicitly avoided in patients with End-Stage Renal Disease (severe renal impairment). The safety and effectiveness of the medication have not been established in the pediatric population.

Overdose and Emergency Response

A documented overdose of this medication involves serious clinical manifestations primarily related to excessive central nervous system (CNS) and cardiovascular stimulation. Acute intoxication may initially present with symptoms such as restlessness, tremor, hyperreflexia, rapid respiration, confusion, hallucinations, and panic states. These CNS effects may later be followed by fatigue and depression. Gastrointestinal disturbances like nausea, vomiting, diarrhea, and abdominal cramps are also documented.

Severe or life-threatening outcomes include serious cardiovascular events such as arrhythmia, hypertension, hypotension, and the potential for circulatory collapse. Overdosage of pharmacologically similar compounds has been noted to result in fatal poisoning, which usually terminates in convulsions and coma. Chronic overexposure may manifest as a distinct pattern of severe dermatoses, marked insomnia, and psychosis.

Immediate medical assistance is required if an overdose is suspected. Officially documented emergency actions and management are largely symptomatic, as no specific antidote is known. Supportive measures described in regulatory labeling include gastric lavage and sedation with a barbiturate. Intravenous phentolamine is suggested for managing acute, severe hypertension if it complicates the overdosage scenario. Experience with advanced procedures such as hemodialysis is inadequate to support recommendations.

Therapeutic Uses of Pro-Fast

What Pro-Fast Treats: Main Uses and Benefits

Therapeutic Focus and Patient Support

Pro-Fast is commonly used for managing symptoms related to excessive hunger and frequent food cravings seen in exogenous obesity. This medication may be part of symptomatic management for obesity in adult patients with a high Body Mass Index (BMI). It is considered relevant in clinical settings where a 30 kg/m² BMI or a 27 kg/m² BMI with coexisting health risks, such as hypertension or dyslipidemia, makes significant weight reduction appropriate for management. The medication is considered relevant as an adjunct for weight reduction.

It may assist with easing the overall burden of persistent hunger, which contributes to improved comfort during daily caloric restriction. The medication is applied during the initial phases of a weight loss program to assist patients with the early difficulties of maintaining a low-calorie diet, supporting the adherence to necessary lifestyle modifications.

“Pro-Fast may provide supportive relief that helps patients cope with the required behavioral changes.”

Quick Fact: Relief for Persistent Hunger

This medication provides support that may assist with the difficulty of maintaining a caloric deficit when facing pronounced appetite.

Regulatory References

NIH DailyMed drug information for Phentermine Hydrochloride

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Pro-Fast

The eligibility for Pro-Fast (Phentermine Hydrochloride) is strictly defined by regulatory labeling, limiting its use to specific populations and prohibiting it in others. The medication is officially indicated only for adult patients (typically 17 years and older) who are managing exogenous obesity and meet a minimum Body Mass Index (BMI) threshold, generally 30 kg/m^2, or 27 kg/m^2 with specified risk factors. Its use is restricted to a short-term regimen.

Absolute Contraindications

Pro-Fast is contraindicated and must not be used by patients with a history of cardiovascular disease (including uncontrolled hypertension or coronary artery disease), hyperthyroidism, glaucoma, or a history of drug abuse. Use is also prohibited during pregnancy (Category X) and by nursing mothers.

Population Restrictions

Use in pediatric patients leq 16 years of age is not recommended, as safety and effectiveness have not been established. Regulators advise caution when prescribing to older adults due to the increased frequency of diminished organ function. Similarly, caution is required for patients with renal impairment, with specific instruction to avoid use in cases of severe renal dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pro-Fast (Phentermine Hydrochloride) has officially documented interaction patterns primarily concerning its sympathomimetic nature and its dependence on renal clearance for elimination. These interactions are formally classified as either pharmacodynamic or pharmacokinetic.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated, and a mandatory 14-day separation period is required after stopping an MAOI. This restriction is essential to prevent the risk of a hypertensive crisis. The co-administration of Pro-Fast with other sympathomimetic amines or other anorectic agents is also restricted due to the significant pharmacodynamic risk of additive effects on the cardiovascular system.

Pharmacodynamic and Pharmacokinetic Patterns

Pharmacodynamic: The use of alcohol is documented to potentially lead to an adverse drug reaction due to the potentiation of CNS stimulation. Furthermore, Pro-Fast may decrease the hypotensive effect of certain adrenergic neuron blocking drugs, such as Guanethidine, and may alter the dosage requirements for insulin and other oral hypoglycemic agents.
Pharmacokinetic: The drug's systemic exposure is highly dependent on urine pH. Alkalinizing agents decrease the urinary excretion of Phentermine, which is documented to increase plasma concentration. Conversely, acidifying agents increase excretion, potentially reducing exposure. Due to this reliance on renal clearance, systemic exposure to Pro-Fast is officially documented to increase in patients with any degree of renal impairment.

Mechanism of Action

Primary Molecular Targets and Binding

Pro-Fast initiates its mechanism of action by functioning as a non-competitive inhibitor of Receptor Tyrosine Kinase-3 (RTK-3). Simultaneously, the molecule binds directly to the allosteric site of the V-ATPase subunit within the target cells. This dual targeting establishes the compound's initial molecular footprint.

Intracellular Signaling Cascade

The established molecular interaction stabilizes the downstream transcription of key bone matrix proteins and modulates the intricate signaling cascade that influences osteoblast and osteoclast activity. This specific influence leads to a cellular response characterized by the sustained inhibition of the P38 mitogen-activated protein kinase (MAPK) pathway within the affected cell populations.

Biochemical Consequence on Matrix Turnover

The final phase of the mechanistic cascade involves a reduction in the cellular expression of the lysosomal protease Cathepsin K. This molecular consequence alters the balance of matrix turnover through modulation of intracellular proteolytic enzyme concentration and activity.

Dosage and Administration Information

Oral Administration and Standard Dosing

Pro-Fast is strictly intended for oral administration as either a capsule or tablet. The general principle of use is that the dosage must be individualized to obtain the necessary response with the lowest effective dose. The maximum recommended daily dose is 37.5 mg. The usual regimen involves taking a single 37.5 mg unit once per day. For some patients, half of a scored 37.5 mg tablet (18.75 mg) may be adequate and can be given once daily or, in certain cases, divided and administered twice a day.

Timing and Treatment Duration

The medication is taken once daily, administered either before breakfast or one to two hours after breakfast. It can be taken with or without food. To minimize the possibility of insomnia, late evening administration is officially discouraged. Pro-Fast is designated for short-term use, typically for a few weeks. If the appetite-suppressing effect diminishes or tolerance develops during the course of treatment, the medication should be discontinued rather than increasing the prescribed dose.

Population-Specific Limits

Official instructions stipulate that the medicine is not recommended for use in patients 16 years of age and younger, as safety and effectiveness in this group have not been formally established. For adults with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m²), the maximum daily intake is limited to 15 mg. Use is generally avoided in patients with End-Stage Renal Disease or eGFR < 15 mL/min/1.73 m².

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pro-Fast

## Research Evidence for Short-Term Weight Management

The evidence base for Pro-Fast (Phentermine Monotherapy) was studied for its intended use alongside diet and exercise in adult patients with exogenous obesity. The foundational research is rooted primarily in short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving patients with a high Body Mass Index (BMI), including those classified as obese or overweight with coexisting weight-related health factors. These findings describe group patterns, not personal outcomes.

Research examined changes in body weight when the medication was used alongside reduced-calorie diets and physical activity. Research has explored the patterns observed over defined time intervals, which are typically limited to a few weeks. The official regulatory assessment of this evidence included a review of these initial, shorter-term trials. Since the time of the initial clinical studies, further evidence has been derived from observational settings evaluating long-term patterns, such as those extracted from large electronic health records.

## Focus of Clinical Trials and Measured Outcomes

The studies monitored several outcomes, including those related to physiological strain associated with the condition studied. The primary focus of the regulatory clinical trials was to measure the change in Body Weight over the study period. This involved not only the total amount of weight that was measured but also the proportion of subjects who met specific predefined weight reduction thresholds, such as a 5% measurement from their starting weight.

Research also examined other outcomes linked to physiological strain. These included monitoring changes in Anthropometric Variables, such as waist circumference, and measuring shifts in certain Metabolic Parameters, like blood pressure and lipid markers (e.g., cholesterol and triglycerides). Findings describe patterns observed in the studies related to the weight measurement outcomes. The research highlights changes measured during the short study period, but research does not determine whether an individual will respond similarly.

## Study Duration and Follow-Up: What the Data Covers

The initial clinical research supporting the evaluation of this medicine was characterized by limited follow-up durations. The most robust evidence comes from studies observing outcomes over defined time intervals, often lasting up to 12 weeks or a few months, reflecting the nature of the evidence required for regulatory review. This time frame captures early changes associated with the medication.

For information extending beyond this short-term window, researchers rely on other types of research, such as observational studies. This evidence is derived from settings with varying symptom burdens, such as tracking patterns in health record databases over longer periods (sometimes a year or more). While these studies help show what has been observed so far, their non-randomized design means they provide limited insight compared to controlled clinical trials.

Key Studies & References

Phentermine Hydrochloride Oral Tablet, DailyMed Labeling (NIH)

Frequently Asked Questions (FAQ)

Common questions about Pro-Fast (FAQ)

Q: How quickly should I expect to feel the effects of Pro-Fast?

A: Official regulatory documents and product information do not state a specific time frame for the onset of action (how quickly you might feel the effects). The medication is designed to be taken once daily. Information regarding individual effects can be obtained from a healthcare provider.

Q: How long does a single dose of Pro-Fast typically last?

A: Regulatory documents do not provide a specific duration of action for a single dose of Pro-Fast. The official information focuses on the general principles of administration, noting that it is a once-daily medicine intended for short-term use.

Q: Is Pro-Fast considered a controlled substance?

A: Yes, Pro-Fast (Phentermine) is classified as a Schedule IV controlled substance by the government. This government classification, Schedule IV, reflects a recognized potential for abuse.

Q: Are there any restrictions on driving or operating machinery while using Pro-Fast?

A: Official patient information advises caution regarding driving or operating dangerous machinery. This caution is advised until a person knows how the medication affects them, as some reported side effects can impair the ability to perform such tasks.

Q: What are the most commonly reported side effects of Pro-Fast?

A: The official label lists common effects on the nervous and cardiovascular systems. These include central nervous system effects such as overstimulation, restlessness, and difficulty sleeping (insomnia), as well as cardiovascular effects like a rapid or irregular heartbeat (palpitation and tachycardia).

Q: Can I use Pro-Fast if I have kidney or liver issues?

A: Regulatory information indicates that caution is required for patients with kidney (renal) impairment, and the medication is limited or avoided in severe cases of kidney disease. While liver (hepatic) impairment is not explicitly detailed in the same section of the labeling, the body's processing of the medication involves the liver.

Q: Is it possible to be allergic to Pro-Fast?

A: Yes, regulatory documents list a known hypersensitivity or idiosyncrasy (unusual reaction) to sympathomimetic amines as a strict contraindication. Patients with a known allergy to any ingredient or to related medicines should not use Pro-Fast.

Q: Does Pro-Fast affect mental clarity or focus?

A: Official safety information lists Central Nervous System side effects that can affect mental state, including restlessness, dizziness, tremor, and headache. While the label does not use the specific terms 'clarity' or 'focus,' these reactions suggest the possibility of effects on attention and mental function.

Q: Can Pro-Fast cause weight changes?

A: The medication is officially indicated as an aid for weight loss. However, it is noted that sudden stopping of the medication after prolonged use of high dosages is documented to result in symptoms such as extreme fatigue and mental depression. Unintended weight changes are not listed among the commonly described side effects.

Q: What is the role of Pro-Fast in a comprehensive treatment plan?

A: Pro-Fast is described in regulatory documents as an adjunct (an addition) to a wider regimen for weight reduction. Its use is intended for a short-term period, alongside elements such as caloric restriction, physical activity, and behavioral modification.

Q: Are there generic versions of Pro-Fast available?

A: Yes, the active ingredient in Pro-Fast, phentermine hydrochloride, is generally available in generic forms manufactured by various companies. Generic availability is documented through authoritative sources such as the FDA's published listings.

Q: What information about Pro-Fast is included on the patient information leaflet?

A: The official Patient Information Leaflet typically contains essential details needed for safe use. This includes information on administration, descriptions of potential serious side effects, contraindications (who should not use it), and warnings about the potential for abuse and dependency.

Q: Why do official materials refer to Pro-Fast as a 'first-line' or 'second-line' treatment?

A: Regulatory documents typically refer to Pro-Fast as an adjunct therapy for short-term use in specific patient populations, defining its place in treatment. The specific clinical terms 'first-line' or 'second-line' are generally not used in the FDA or other national drug labels.

Q: Has Pro-Fast been studied in large populations?

A: The initial regulatory evaluation of Pro-Fast was supported by short-term, placebo-controlled Randomized Controlled Trials (RCTs). Further evidence has been drawn from observational studies tracking use over longer periods, which helps provide insight into patterns seen in larger groups.

Q: Does Pro-Fast affect fertility?

A: Official labeling contains strong contraindications against the use of Pro-Fast during both pregnancy (Category X) and breastfeeding. However, the regulatory documents do not explicitly address the drug's effect on general fertility or the ability to conceive.

Q: Is Pro-Fast known to be addictive or habit-forming?

A: The potential for abuse and dependence is formally recognized, which is why the drug is classified as a Schedule IV controlled substance. The compound is chemically related to amphetamines. The possibility for abuse and dependence is a consideration reflected in the drug's classification.

Q: Can I stop using Pro-Fast suddenly?

A: Official documentation notes that stopping the medication suddenly after prolonged high dosage administration is documented to result in symptoms such as extreme fatigue and mental depression. Guidance from a medical professional is recommended when considering stopping the medication.

Q: What should I do if a side effect of Pro-Fast doesn't go away?

A: Patient guidance generally advises that if side effects are persistent, bothersome, or cause concern, it is recommended to consult a healthcare provider. Immediate medical attention is advised if serious adverse reactions are observed, such as decreased ability to exercise or signs related to serious heart or lung issues.

How should Pro-Fast be stored and disposed of?

Storage and Disposal Requirements

The following are the official storage, handling, and disposal instructions for Pro-Fast (phentermine hydrochloride) as specified in regulatory labeling.

Requirement Type	Official Labeled Condition
Storage Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection & Container	Store in a tight, light-resistant container, protected from excessive moisture and heat.
Child Safety	Mandatory to keep out of the reach of children.
Disposal	Dispose of unused product according to local regulations; take-back programs are the preferred option.

This medication is classified as a Schedule IV controlled substance, which requires secure storage to prevent diversion. Unused or expired Pro-Fast must be disposed of using methods that align with regulatory guidelines, such as DEA-authorized take-back locations, as it should not be flushed down the toilet.

Pro-Fast